Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase

Cancer Science

Volumn 98, Issue 6, 2007, Pages 815-821

  Ishida, Maki ^a   Ichihara, Masatoshi ^a,b   Mii, Shinji ^a   Jijiwa, Mayumi ^a   Asai, Naoya ^a   Enomoto, Atsushi ^a   Kato, Takuya ^a   Majima, Ai ^a   Ping, Jiang ^a   Murakumo, Yoshiki ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; PROTEIN TYROSINE KINASE; SPROUTY PROTEIN; SPROUTY1 PROTEIN; SPROUTY2 PROTEIN; SPROUTY3 PROTEIN; SPROUTY4 PROTEIN; TRANSCRIPTION FACTOR ELK 1; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NERVE FIBER GROWTH; NEUROBLASTOMA; NEUROBLASTOMA CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WILD TYPE;

CELL DIFFERENTIATION; CELL PROLIFERATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE KINASE KINASE 3; NEURITES; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 34247869867     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00457.x     Document Type: Article

References (38)

1. Airaksinen MS, Saarma M. The GDNF family: Signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3: 383-94.
2. Manie S, Santoro M, Fusco A, Billaud M. The RET receptor: Function in development and dysfunction in congenital malformation. Trends Genet 2001; 17: 580-9.
3. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004; 204: 197-211.
4. Kodama Y, Asai N, Jijiwa M, Murakumo Y, Ichihara M, Takahashi M. The RET proto-oncogene: A molecular therapeutic target in thyroid cancer. Cancer Sci 2005; 96: 143-8.
5. Asail N, Jijiwa M, Enomoto A et al. RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease. Pathol Int 2006; 56: 164-72.
6. Besset V, Scott RP, Ibanez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 2000; 275: 39 159-66.
7. Hayashi H, Ichihara M, Iwashita T et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000; 19: 4469-75.
8. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000; 275: 3568-76.
9. Borrello MG, Alberti L, Arighi E et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 1996; 16: 2151-63.
10. Hayashi Y, Iwashita T, Murakami H et al. Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation. Biochem Biophys Res Commun 2001; 281: 682-9.
11. Fukuda T, Kiuchi K, Takahashi M. Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. J Biol Chem 2002; 277: 19 114-21.
12. Fukuda T, Asai N, Enomoto A, Takahashi M. Activation of c-Jun amino-terminal kinase by GDNF induces G2/M cell cycle delay linked with actin reorganization. Genes Cells 2005; 10: 655-63.
13. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994; 367: 380-3.
14. Moore MW, Klein RD, Farinas I et al. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996; 382: 76-9.
15. Pichel JG, Shen L, Sheng HZ et al. GDNF is required for kidney development and enteric innervation. Cold Spring Harb Symp Quant Biol 1996; 61: 445-57.
16. Sanchez MP, Silos-Santiago I, Frisen J, He B, Lira SA, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996; 382: 70-3.
17. Meng X, Lindahl M, Hyvonen ME et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 2000; 287: 1489-93.
18. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001; 12: 361-73.
19. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998; 92: 253-63.
20. Reich A, Sapir A, Shilo B. Sprouty is a general inhibitor of receptor tyrosine kinase signaling. Development 1999; 126: 4139-47.
21. Mason JM, Morrison DJ, Basson MA, Licht JD. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 2006; 16: 45-54.
22. Lee SH, Schloss DJ, Jarvis L, Krasnow MA, Swain JL. Inhibition of angiogenesis by a mouse sprouty protein. J Biol Chem 2001; 276: 4128-33.
23. Impagnatiello MA, Weitzer S, Gannon G, Compagni A, Cotten M, Christofori G. Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol 2001; 152: 1087-98.
24. Taketomi T, Yoshiga D, Taniguchi K et al. Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia. Nat Neurosci 2005; 8: 855-7.
25. Sasaki A, Taketomi T, Wakioka T, Kato R, Yoshimura A. Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor-but not epidermal growth factor-induced ERK activation. J Biol Chem 2001; 276: 36 804-8.
26. Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins. J Biol Chem 1996; 271: 17 644-9.
27. Hanafusa H, Torii S, Yasunaga T, Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 2002; 4: 850-8.
28. Uchida M, Enomoto A, Fukuda T et al. Dok-4 regulates GDNF-dependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase. J Cell Sci 2006; 119: 3067-77.
29. Ozaki K, Kadomoto R, Asato K, Tanimura S, Itoh N, Kohno M. ERK pathway positively regulates the expression of Sprouty genes. Biochem Biophys Res Commun 2001; 285: 1084-8.
30. Minowada G, Jarvis LA, Chi CL et al. Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 1999; 126: 4465-75.
31. Jijiwa M, Fukuda T, Kawai K et al. A targeting mutation of tyrosine 1062 in ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol Cell Biol 2004; 24: 8026-36.
32. Asai N, Fukuda T, Wu Z et al. Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. Development 2006; 133: 4507-16.
33. Hishiki T, Isogai E, Kondo K et al. Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFRα-1, and GFRα-2. Cancer Res 1998; 58: 2158-65.
34. Chao MV. Neurotrophins and their receptors: A convergence point for many signaling pathways. Nat Rev Neurosci 2003; 4: 299-309.
35. Basson MA, Akbulut S, Watson-Johnson J et al. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell 2005; 8: 229-39.
36. Basson MA, Watson-Johnson J, Shakya R et al. Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Dev Biol 2006; 229: 466-77.
37. Lo TL, Fong CW, Yusoff P et al. Sprouty and cancer: The first terms report. Cancer Lett 2006; 242: 141-50.
38. Tsavachidou D, Coleman ML, Athanasiadis G et al. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 2004; 64: 5556-9.